Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Down 39.5% in June

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 19,653 shares, a decline of 39.5% from the June 15th total of 32,466 shares. Based on an average daily volume of 17,349 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.1% of the shares of the stock are sold short.

Guided Therapeutics Stock Performance

Guided Therapeutics stock remained flat at $0.27 during midday trading on Thursday. The company had a trading volume of 23,501 shares, compared to its average volume of 8,782. The company has a market cap of $26.07 million, a PE ratio of -6.75 and a beta of 0.72. The business’s 50 day moving average price is $0.23 and its two-hundred day moving average price is $0.29. Guided Therapeutics has a 52 week low of $0.12 and a 52 week high of $0.54.

Guided Therapeutics (OTCMKTS:GTHP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.01) EPS for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.